Your browser doesn't support javascript.
loading
Potent antitumour of the mTORC1/2 dual inhibitor AZD2014 in docetaxel-sensitive and docetaxel-resistant castration-resistant prostate cancer cells.
Li, Senmao; Sheng, Jindong; Liu, Zhenhua; Fan, Yu; Zhang, Cuijian; Lv, Tianjing; Hu, Shuai; Jin, Jie; Yu, Wei; Song, Yi.
Afiliação
  • Li S; Department of Urology, Beijing Key Laboratory of Urogenital Diseases (Male), Molecular Diagnosis and Treatment Center, National Research Center for Genitourinary Oncology, Peking University First Hospital and Institute of Urology, Peking University, Beijing, China.
  • Sheng J; Department of Gynaecological Oncology, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin's Clinical Research Center for Cancer, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
  • Liu Z; Department of Urology, Beijing Key Laboratory of Urogenital Diseases (Male), Molecular Diagnosis and Treatment Center, National Research Center for Genitourinary Oncology, Peking University First Hospital and Institute of Urology, Peking University, Beijing, China.
  • Fan Y; Department of Urology, Beijing Key Laboratory of Urogenital Diseases (Male), Molecular Diagnosis and Treatment Center, National Research Center for Genitourinary Oncology, Peking University First Hospital and Institute of Urology, Peking University, Beijing, China.
  • Zhang C; Department of Urology, Beijing Key Laboratory of Urogenital Diseases (Male), Molecular Diagnosis and Treatment Center, National Research Center for Genitourinary Oncology, Peking University First Hospital and Institute of Urology, Peking University, Beijing, China.
  • Lv T; Department of Urology, Beijing Key Laboratory of Urogenital Diseases (Male), Molecular Diagnosis and Treatment Center, National Research Center for Genitourinary Oncology, Peking University First Hospital and Institute of Urology, Peking University, Beijing, China.
  • Hu S; Department of Urology, Beijing Key Laboratory of Urogenital Diseases (Male), Molecular Diagnosis and Treatment Center, National Research Center for Genitourinary Oncology, Peking University First Hospital and Institute of Urology, Peking University, Beijing, China.
  • Jin J; Department of Urology, Beijing Key Laboratory of Urogenital Diseases (Male), Molecular Diagnosis and Treatment Center, National Research Center for Genitourinary Oncology, Peking University First Hospital and Institute of Urology, Peking University, Beijing, China.
  • Yu W; Department of Urology, Beijing Key Laboratory of Urogenital Diseases (Male), Molecular Diagnosis and Treatment Center, National Research Center for Genitourinary Oncology, Peking University First Hospital and Institute of Urology, Peking University, Beijing, China.
  • Song Y; Department of Urology, Beijing Key Laboratory of Urogenital Diseases (Male), Molecular Diagnosis and Treatment Center, National Research Center for Genitourinary Oncology, Peking University First Hospital and Institute of Urology, Peking University, Beijing, China.
J Cell Mol Med ; 25(5): 2436-2449, 2021 03.
Article em En | MEDLINE | ID: mdl-33507584
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 6_ODS3_enfermedades_notrasmisibles Base de dados: MEDLINE Assunto principal: Pirimidinas / Benzamidas / Morfolinas / Resistencia a Medicamentos Antineoplásicos / Inibidores de Proteínas Quinases / Alvo Mecanístico do Complexo 1 de Rapamicina / Alvo Mecanístico do Complexo 2 de Rapamicina Tipo de estudo: Diagnostic_studies Limite: Humans / Male Idioma: En Revista: J Cell Mol Med Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 6_ODS3_enfermedades_notrasmisibles Base de dados: MEDLINE Assunto principal: Pirimidinas / Benzamidas / Morfolinas / Resistencia a Medicamentos Antineoplásicos / Inibidores de Proteínas Quinases / Alvo Mecanístico do Complexo 1 de Rapamicina / Alvo Mecanístico do Complexo 2 de Rapamicina Tipo de estudo: Diagnostic_studies Limite: Humans / Male Idioma: En Revista: J Cell Mol Med Ano de publicação: 2021 Tipo de documento: Article